JNCE - Jounce Therapeutics: A Favorable Risk-Reward Ahead Of Critical 2022 Catalysts

• Jounce is making an attempt to renovate how we treat cancer by developing novel immunotherapies that could expand these treatments to new patients and tumor types.
• The company’s platform and R&D capabilities are impressive. If all goes well, Jounce could have several blockbuster drugs in their pipeline.
• Jounce has an attractive license deal with Gilead, which has provided some cash with milestones and royalties.
• The company expects to report data from their INNATE study and their SELECT study in 2022. If the data is promising, the market should react positively as they recognize the prospect JNCE provides.

For further details see: